Back to top
more

McKesson (MCK)

(Delayed Data from NYSE)

$552.39 USD

552.39
876,845

-11.61 (-2.06%)

Updated May 21, 2024 04:00 PM ET

After-Market: $553.10 +0.71 (0.13%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value A Growth B Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 34% (164 out of 248)

Industry: Medical - Dental Supplies

Better trading starts here.

Zacks News

Quality Systems Ties Up With CoverMyMeds to Enable ePA

Quality Systems' (QSII) new collaboration with CoverMyMeds sees bright market prospects.

    Cerner (CERN) Strong on EHR Prospects, Competition Intense

    Cerner's (CERN) strong EHR prospects and global outlook aid the company; margins continue to decline.

      Cardinal Health Product Spectrum Broad, Competition Rife

      Cardinal Health's (CAH) strategic buyouts lend it a competitive edge; the Cordis unit lacks luster.

        Allscripts' Payerpath & ePrescribe Receive EHNAC Accreditation

        Accreditation by EHNAC indicates Allscripts' (MDRX) sustainability in health data processing and transactions in terms of industry-established standards and HIPAA regulations.

          Allscripts Gains From Strong Results in Q2, Competition Rife

          Allscripts (MDRX) continues to gain from solid Q2 results and EHR developments; a competitive industry is a concern.

            McKesson (MCK) Beats on Q1 Earnings, Reiterates '19 View

            Strong prospects in Medical-Surgical business drove McKesson's (MCK) Q1. However, the company witnesses solid regulatory hurdles in the McKesson Canada business.

              McKesson's (MCK) Q1 Earnings Beat Estimates, Sales Improve Y/Y

              McKesson???s Q1 results were driven by solid performance in Medical-Surgical Solutions segment.

                McKesson (MCK) Q1 Earnings Top Estimates

                McKesson (MCK) delivered earnings and revenue surprises of 0.35% and -0.82%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?

                  Medical Product Earnings Lineup for Jul 26: BAX, EW & More

                  Streak of regulatory developments and deep R&D focus are likely to drive the Medical Product industry this earnings season. Here we take a quick look at four Medical Product majors that are going to release earnings results.

                    Will 5 Elements Drive Quest Diagnostics (DGX) Q2 Earnings?

                    Per Quest Diagnostics (DGX), growing strength of partnerships with health care leaders and strategic acquisitions are creating growth prospects for the top and bottom-line growth.

                      Can Established Pharmaceuticals Up Abbott (ABT) Q2 Earnings?

                      According to Abbott (ABT), key emerging markets represent the most attractive long-term growth opportunities for its branded generics product portfolio within EPD.

                        Can Abbott (ABT) Rise on Robust Overall Growth in Q2 Earnings?

                        Abbott (ABT) gains traction from a steady healthy growth trajectory seen in core Diabetes Care business.

                          Will Flagship Impella Drive Abiomed's (ABMD) Q1 Earnings?

                          Abiomed's (ABMD) first-quarter fiscal 2019 earnings are likely to be driven by an exclusive Impella product line. Intense competition raises concern.

                            Can International Sales Drive Baxter's (BAX) Q2 Earnings?

                            Baxter's (BAX) Q2 earnings likely to be aided by promising international ventures and acquisitions; cyclophosphamide competition raises concern.

                              Will Core Distribution Unit Aid McKesson (MCK) Q1 Earnings?

                              Strong prospects in the Distribution Solutions segment is likely to boost McKesson's (MCK) top-line performance in the fiscal first quarter.

                                Will Core Segmental Growth Aid Stryker (SYK) in Q2 Earnings?

                                Stryker's (SYK) strong segmental performance and acquisition-driven strategy are likely to drive Q2 earnings.

                                  Should Value Investors Consider McKesson (MCK) Stock Now?

                                  Let's see if McKesson Corporation (MCK) stock is a good choice for value-oriented investors right now, or if investors subscribing to this methodology should look elsewhere for top picks.

                                    Sweta Jaiswal headshot

                                    Amazon Forays Into Pharmacy Business: Red Alert for Others?

                                    Amazon's entry into the high-potential pharmaceutical industry deals a blow to share prices of major players.

                                      McKesson (MCK) Issues Strong Preliminary Results for Q1

                                      McKesson Corporation (MCK) declares solid preliminary results for Q1, courtesy of deals, divestitures and acquisitions.

                                        Why Is McKesson (MCK) Up 1.7% Since Its Last Earnings Report?

                                        McKesson (MCK) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

                                          McKesson's (MCK) Q4 Earnings Miss Estimates, Sales Improve Y/Y

                                          McKesson (MCK) witnesses strong growth in its Distribution Solutions segment in Q4 of fiscal 2018.

                                            Is McKesson Corporation (MCK) a Suitable Value Stock Now?

                                            Let's see if McKesson Corporation (MCK) stock is a good choice for value-oriented investors right now, or if investors subscribing to this methodology should look elsewhere for top picks.

                                              Mark Vickery headshot

                                              Top Stock Reports for Lockheed Martin, Mastercard & Colgate

                                              Today's Research Daily features new research reports on 16 major stocks, including Lockheed Martin (LMT), Mastercard (MA) and Colgate (CL).

                                                McKesson (MCK) Beats on Earnings and Sales in Q3

                                                McKesson Corporation (MCK) delivers strong performance on the back of solid organic growth.

                                                  McKesson (MCK) Beats on Earnings and Sales in Q2

                                                  McKesson's adjusted earnings of $3.28 per share came above the Zacks Consensus Estimate of $2.78 and increased from $2.96 in the year-ago quarter.